Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR3A | P46098 | 1/20 | 0.66 |
| ▸ | JAK3 | P52333 | 1/20 | 0.49 |
| ▸ | SLC18A3 | Q16572 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.47 |
| ▸ | HTR2C | P28335 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1002475 | 1.00 | HTR3A (0.66) | HTR3AJAK3SLC18A3SIGMAR1HTR2C | |
| Hydrochloric Acid SCHEMBL15300834 | 0.98 | HTR3A (0.63) | HTR3AJAK3SLC18A3SIGMAR1HTR2C | |
| SCHEMBL83831 | 0.90 | HTR3A (0.53) | HTR3A | |
| SCHEMBL15777910 | 0.90 | HTR3A (0.53) | HTR3A | |
| SCHEMBL998429 | 0.90 | HTR3A (0.53) | HTR3A | |
| Hydrochloric Acid SCHEMBL29969490 | 0.88 | HTR3A (0.52) | HTR3A | |
| Hydrochloric Acid SCHEMBL19459257 | 0.88 | HTR3A (0.52) | HTR3A | |
| Hydrochloric Acid SCHEMBL19459131 | 0.88 | HTR3A (0.52) | HTR3A | |
| SCHEMBL181015 | 0.87 | SLC18A3 (0.61) | HTR3ASLC18A3SIGMAR1HTR2C | |
| Formic Acid Methyl Ester SCHEMBL27957967 | 0.85 | HTR3A (0.50) | HTR3AJAK3HTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4466260-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | Astrazeneca AB (SE) | 2024-11-27 | — | — | EP | disclosed |
| CN-118574821-A | Compounds and their use in the treatment of cancer | 阿斯利康(瑞典)有限公司 | 2024-08-30 | — | — | CN | disclosed |
| WO-2023139199-A1 | COMPOUNDS AND THEIR USE IN TREATING CANCER | ASTRAZENECA AB (SE) | 2023-07-27 | — | — | WO | disclosed |
| CN-102036955-B | Hydroxamate-based inhibitors of deacetylase B | NOVARTIS AG | 2013-03-27 | — | — | CN | disclosed |
| WO-2011076678-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2011-06-30 | — | — | WO | disclosed |
| CN-102036955-A | Hydroxamate-based inhibitors of deacetylase B | NOVARTIS AG | 2011-04-27 | — | — | CN | disclosed |